Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Bionanomatrix to Co-develop Genetic Analysis System

NEW YORK (GenomeWeb News) – Agilent Technologies and BioNanomatrix will team to develop an integrated genetic analysis system with applications in genotoxicity and cytogenetics assay development, and potentially DNA sequencing, the companies said today.
Under the agreement, the companies plan to combine BioNanomatrix’s single-molecule imaging technology to develop chips and reagents with a measurement platform developed by Agilent.
Philadelphia-based BioNanomatrix is currently developing nanoscale single-molecule technology that will enable identification and analysis of an entire genome, the company said. The firm recently formed a joint venture with Complete Genomics to use an $8.8 million grant from the US National Institute of Standards and Technology to develop a platform aimed at sequencing a human genome in eight hours for under $100.
“BioNanomatrix’s unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine,” said Agilent GM of Life Sciences Solutions Nick Roelofs.
Financial terms of the agreement were not released.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.